New Zealand at a glance
- Population
- 5.3 million 2025
- Life expectancy at birth
- 82.0 years, 2024
- People aged 65 and over
- 17.6 % of people, 2025
- Health spending per person
- 5,022 US$ per person, 2024
- Doctors
- 3.61 per 1,000 people, 2022
Updated
Reviewed by Chandani Patel
New Zealand HPV Testing Market Industry Trends and Forecast to 2034: Segmented by (Test, Sample, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$25.1 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $13.2 Mn | — | — |
| 2025 (base) | $14.7 Mn | +$1.5 Mn | — |
| 2026 (forecast) | $16.4 Mn | +$1.7 Mn | +11.7% |
| 2027 (forecast) | $18.4 Mn | +$1.9 Mn | +24.8% |
| 2028 (forecast) | $20.5 Mn | +$2.1 Mn | +39.4% |
| 2029 (forecast) | $22.9 Mn | +$2.4 Mn | +55.7% |
| 2030 (forecast) | $25.6 Mn | +$2.7 Mn | +73.9% |
| 2031 (forecast) | $28.6 Mn | +$3.0 Mn | +94.2% |
| 2032 (forecast) | $31.9 Mn | +$3.3 Mn | +117% |
| 2033 (forecast) | $35.7 Mn | +$3.7 Mn | +142.3% |
| 2034 (forecast) | $39.9 Mn | +$4.2 Mn | +170.7% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $14.7 Mn placeholder estimate |
|---|---|
| Forecast, 2034 | $39.9 Mn placeholder estimate |
| Growth (CAGR), 2025–2034 | 11.7% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Test, sample and end user (see all) |
| Key players | Roche Diagnostics, Hologic, Inc., Qiagen N.V., BD (Becton, Dickinson), Abbott Laboratories (see all) |
| Regulator in New Zealand | Medsafe (WAND)Source: Medsafe. Checked 14 Nov 2026. |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
HPV testing detects human papillomavirus types that can cause cervical cancer, used for cervical screening, including self-collected samples.
Key segments of the HPV Testing market include test (HPV DNA Tests, HPV mRNA Tests and Genotyping Tests) and sample (Clinician-Collected and Self-Collected).
Greater awareness of women's health needs, more funding for female-focused research, later pregnancies and an ageing female population are driving the HPV Testing market. New products designed around women's biology and digital care are improving access.
Femtech, personalised care and new treatments for under-served conditions open strong growth for the HPV Testing market, especially as employers and payers add women's health benefits.
Under-diagnosis, stigma around some conditions, limited insurance coverage and a long history of under-research in women's health hold back the HPV Testing market.
The HPV Testing market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Medical devices do not need approval before sale, but suppliers must notify them to the WAND database run by Medsafe.[1] Pharmac decides which medicines and medical devices the public health system pays for.[2]
Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how HPV Testing products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in New Zealand.
What doctors and scientists are doing in HPV Testing right now, from free public sources.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 17 Nov 2026.
[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 18 Nov 2026.
[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 18 Nov 2026.
From our blog
New Zealand
New Zealand
New Zealand
New Zealand
New Zealand
New Zealand
Digital Health · New Zealand
Healthcare Services · New Zealand
Pharmaceuticals · New Zealand
Pharmaceuticals · New Zealand
Healthcare Services · New Zealand
Pharmaceuticals · New Zealand